Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selectionLONDON, May 22, 2024 /PRNewswire/ NeoPhore
/PRNewswire/ NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic collaboration agreement.
CAMBRIDGE, England, July 28, 2022 /PRNewswire/ NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has entered a three-year research collaboration
Share this article
Round led by Claris Ventures with 2Invest, 3B Future Health Fund and Astellas Venture Management
CAMBRIDGE, England, March 9, 2021 /PRNewswire/ NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the close of a £15.2m (US $21m) Series B round. The syndicate was led by Claris Ventures and included 2Invest, 3B Future Health Fund and Astellas Venture Management alongside founding investor the CRT Pioneer Fund.
NeoPhore is focused on the discovery and development of novel first-in-class small molecule drugs targeting the DNA mismatch repair (MMR) pathway to treat cancer. NeoPhore will work closely with its scientific founder Dr Alberto Bardelli from the University of Turin where the original scientific discovery originated and Dr Luis Diaz (Memorial Sloan Kettering and SAB member) to exploit the concept that inhibition of MMR in tumours generates neoantigens that the patients own immune system can target with a powerful a
NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.